Mon, Mar 25, 2013 12:45 PM
Resolving outstanding patent litigation
Egis and its business partner Actavis (formerly Watson), have reached a settlement agreement with AstraZeneca related to the generic version of Crestor® tablets (rosuvastatin calcium)as well as rosuvastatin zinc alternate salt product developed by Egis.

Egis Pharmaceuticals PLC (Egis) announces that Egis and its business partner Actavis, Inc. (Partner), formerly known as Watson Pharmaceuticals, Inc., have reached a settlement agreement with AstraZeneca resolving the outstanding patent litigation related to the generic version of Crestor® tablets (rosuvastatin calcium), as well as rosuvastatin zinc alternate salt product developed by Egis. Under the terms of the settlement agreement, the Partner can launch its rosuvastatin calcium product, the generic version of Crestor® 67 days prior to July 8, 2016, the expiration of pediatric exclusivity, or earlier under certain circumstances.

Related file

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox